The Phadia 2500+ Instrument Family Now Available in the U.S. for Autoimmune Testing

Thermo Fisher Scientific (PRNewsfoto/Thermo Fisher Scientific)

PORTAGE, Mich.– The new Phadia 2500+ series of instruments is now available for autoimmune testing in the U.S. The family of high-capacity, intuitive lab instruments supplied by Thermo Fisher Scientific, the world leader in serving science, offers reliable and unparalleled high throughput for both allergy diagnostics and autoimmune testing.

This expanded capability of the Phadia 2500+ series of instruments allows for instrument consolidation and enables additional automation for EliA autoimmune diagnostics, aiding in the diagnosis of autoimmune diseases including Connective Tissue Disease (CTD), Antiphospholipid Syndrome (APS), Celiac Disease, Rheumatoid Arthritis, Autoimmune Liver Disease and Autoimmune Thyroid Disease.

“Increasingly, laboratorians are being asked to further streamline their workflows and become more efficient,” said Michele Zwickl, vice president, commercial operations, U.S., ImmunoDiagnostics, Thermo Fisher. “With the launch of the Phadia 2500+ series, we now offer scalable, high-capacity allergy and autoimmune diagnostics instrumentation that can help large labs be more productive with existing resources.”

The Phadia 2500+ series of instruments is capable of serving laboratories with demands exceeding 10,000 test results every week and maximizes productivity by providing options to run EliA and ImmunoCAP testing in parallel on a single instrument. Its high throughput automation allows laboratories to process up to 480 ImmunoCAP results per hour and up to 300 EliA autoimmunity results per hour.